Zogenix (ZGNX +6.7%) moves up after announcing its preliminary Q4 sales figures today. The company expects gross product sales of approximately $13.5M on 145,200 units shipped, with unit volume up approximately 9% sequentially from Q312 and 26% from Q411. For FY12, preliminary unaudited net product revenues were around $36M, up 18% over FY11, but slightly below previously issued guidance of $37M. Separately the drug developer adds that it's filed for a $75M mixed shelf registration.
Zogenix (ZGNX +6.7%) moves up after announcing its preliminary Q4 sales figures today. The...
From other sites
at CNBC.com (Apr 10, 2014)
at CNBC.com (Mar 14, 2014)
Video at CNBC.com (Mar 11, 2014)
at CNBC.com (Mar 5, 2014)
at CNBC.com (Oct 28, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs